Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Playtech B2B unit hits medium-term targets in 'landmark year'

(Sharecast News) - Software developer Playtech said on Thursday that its business-to-business unit had hit medium-term targets ahead of schedule in what it branded a "landmark year". Playtech said reported underlying earnings had fallen 12% in FY24 to €358.8m, while revenues were up 5% at €1.79bn. However, on an adjusted basis, EBITDA was up 11% at €480.4m and post-tax profits surged 42% to €223.5m.

The FTSE 250-listed firm also drastically reduced its net debt position by 49% to €142.8m following the €2.3bn sale of Snaitech to Flutter, as well as "material improvement" in cash flow generation.

Playtech stated its performance was driven by "strong momentum" in B2B, which saw adjusted EBITDA grow 22% to €222.0m, reaching its medium-term target range of €200.0m-250.0m ahead of schedule.

Chief executive Mor Weizer said: "2024 marked Playtech's 25th anniversary, and was a year of transformational change for the business. The expected sale of Snaitech to Flutter Entertainment will deliver significant returns for shareholders, while the revised agreement with Caliplay will underpin Playtech's future growth as a predominantly pure-play B2B business. The group also delivered an excellent financial performance, with adjusted EBITDA (including Snaitech) slightly ahead of previously raised expectations."

As of 1020 GMT, Playtech shares were up 0.55% at 737.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.